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ORIGINAL RESEARCH
Background: Nearly 5 million children in the United States are affected by asthma, which is
more than 5% of the population younger than 18 years. In children four years or younger, the
prevalence increased 160% from 1980 to 1994. There are several effective drugs that relieve
the symptoms of asthma and others are currently being developed, but even when these
medications are prescribed, they may be underutilized because parents fear the possibility of
adverse events. There is no knowledge whether caregivers would be willing to pay (WTP) for
safe and effective medications in general.
Material and methods: In a conjoint analysis, the status quo and hypothetical treatment
options are defined by four attributes: episode-free days, risk of exacerbation, information
available on the long-term impact of the treatment, and out-of-pocket expenses. Based on
random utility theory, a binary purchase decision equation is specified and estimated using
probit. Several tests were performed with regards to the scaling of the attribute variables, the
linearity of the utility function used, and the derivation of a final model.
Results and conclusions: Marginal willingness-to-pay per month for 20 additional episode-
free days due to a new treatment turns out to be US$6.00. An interesting question from the
(industry) policy point of view for possible new products is the amount of WTP for the product
as a whole. Assuming that the final model is correctly specified, the (negative) constant may
be interpreted as indicating that caregivers feel confident with the asthma treatment options
already on the market and having hence not a positive relation to a new treatment.
Keywords: willingness-to-pay; conjoint analysis, preference study, health economics, discrete-
choice analysis
Introduction
Asthma is a chronic disease that effects between 9 and 12 million persons in the US
(Weiss et al 1992) and is the most common chronic disease of childhood (CDCP
2000). Nearly 5 million children in the US are affected by asthma, which is more
than 5% of the population younger than 18 years (Adams and Marano 1994). Asthma
is the leading cause of lost school days in children (Taylor and Newacheck 1992;
Graves 1993). In children four years or younger, its prevalence increased 160% from
1980 to 1994. There are several effective drugs that relieve the symptoms of asthma,
and more are currently being developed. However, compliance is far from perfect
because parents as caregivers fear the possibility of adverse drug reactions. The
objective of this study is to measure the importance of these concerns in comparison
with the benefits of treatment using willingness-to-pay (WTP) estimates derived
from a discrete-choice experiment (DCE).
For an economic evaluation (such as a discrete-choice analysis) of treatments in
diseases such as asthma, where a substantial impact is on quality of life rather than
survival, it is crucial to be able to incorporate the effects of the new therapies on
quality of life and include those effects in the economic evaluation. Since there are
many health insurances in the US that have a co-payment rate for the insured in their
contract, considerations of relative effectiveness could be complemented by WTP
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estimates. Within healthcare there is substantial evidence
to suggest that, in addition to the treatment outcome (that
is, the effectiveness), other aspects of the process of
receiving treatment are also important for individuals (Ryan
and Hughes 1997; Ratcliffe and Buxton 1999; Ryan 1999;
Johansson et al 2004). The present study analyzes
hypothetical products for the treatment of (preschool)
asthma defined by four attributes. The target population is
children with a maximum age of 4 years. Obviously the
possibility to ask the children themselves was naturally
limited and hence the caregivers answered for them.
The purpose of this study is to calculate, using discrete
choice analysis, the WTP of caregivers with asthmatic
children for different (hypothetical) treatments defined by
four attributes. Additionally the marginal WTP for an
improvement in efficacy (episode-free days) was analyzed.
Furthermore the analyses were done for the whole study
cohort as well as for various risk averse groups.
Material and methods
The DCE (The study protocol was conducted in accordance
with the Declaration of Helsinki and approved by local ethics
committees, and all caregivers gave written informed
consent) performed in this study rests on Lancaster’s theory
of demand (1971), which states consumers value not so
much the quantities of consumer goods but their qualities
and attributes. In the present context the consumer is a
caregiver of at least one asthmatic child with the age of less
than four years, and the commodities in question are
treatment options defined by four attributes. Thus the
preferences of caregivers substitute for those of their patients
(which would have been far more difficult to investigate).
Caregivers were asked to choose between pairs of asthma
treatments for their child, viz. a fixed status quo and a new
(hypothetical) alternative whose attribute levels changed in
the course of the DCE. Attributes and their levels were
pretested in face-to-face interviews with six caregivers in
the autumn of 2005. Original attributes were ease of
handling, efficacy (episode-free days), time for
administration of treatment, number of administrations per
day, side-effects (risk of asthmatic exacerbation),
information on long-term effects in children between 4 and
14 years of age (provided by the Food and Drug
Administration [FDA]) and out-of-pocket cost. The presence
or absence of side effects (EXACERBATION) was deemed
important without exception (see Table 1). The other retained
attributes are episode-free days (FREEDAYS), available
information provided by the FDA (INFORMATION), and
the out-of-pocket cost of the treatment (EXPENSE).
The levels of attributes were defined as follows (see
Table 2). FREEDAYS, symbolizing the change in the
number of episode-free days from a baseline value of 180
days per year (Pauwels et al 1997). Increases are to 200 and
220 days, decreases are to 160 and 140 days, respectively.
EXACERBATION varies between 6%, 10%, and 16%,
indicating the share of patients who develop mild to severe
exacerbation. A recent study with adults has shown that mild
to moderate asthmatic exacerbation causes a marked
decrease of well-being (Jongste et al 2002). This is assumed
to hold true in preschool children. In INFORMATION on
long-term effects specifically in children between 4 and 14
years of age, a study has found that caregivers are concerned
if information is lacking about the long-term effects of
asthma treatment in preschool children (Gibson et al 1995).
Finally, EXPENSES ranges from $10, $30, to $50. Status
quo treatment (see Table 3) was defined as having 180
episode-free days per year and a 10% risk developing mild
to severe exacerbation of asthma with information provided
by FDA and a monthly out-of-pocket cost of $20.
Since these attributes have 4, 3, 2, and 3 levels,
respectively, the number of scenarios amounts to a total of
72 (= 4*3*2*3). This number would cause interviews of
excessive length. Using the ORTHOPLAN procedure of
SPSS (SPSS Inc., Chicago, Il, USA), the design was reduced
to 16 scenarios while this still permits to infer utility values
for all combinations of attribute levels (Louviere et al 2000).
All study participants had to answer these 16 variants, whose
Table 1 Characteristics of individuals from the pretest
N=6 caregivers Percent Cumulative
percent
Gender
  Female 83.3
Age
   ≤ ≤ ≤ ≤ ≤35 years 66.6
   >35 years 33.3 100
Number of children ≤ ≤ ≤ ≤ ≤4 years
  1 child 50
  2 children 50 100
Most important attributes
  Efficacy (episode-free days) 83.3
  Ease of handling 50
  Side effects (exacerbation) 100
  Long-term information available 83.3
  Out-of-pocket expenses 83.3
  Number of administrations per day 66.6
  Time for administration 66.6Therapeutics and Clinical Risk Management 2007:3(1) 159
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sequence was randomized to avoid possible ordering bias
(Gibson et al 1995). Each time respondents had to indicate
whether or not they preferred the treatment or the status
quo (for a sample card presented to study participants, see
Appendix A1).
Due to financial constraints, only 42 respondents were
included in the study. However, to test the validity and
significance of parameter estimates, a Monte-Carlo
simulation yielding comparison estimates was also
performed. The survey was conducted online in February
2006. The questionnaire also covered socioeconomic
characteristics, subjective health status (chronic or other
diseases) of the caregiver, specifics of the asthma treatment,
and diagnosis of the physician.
Choices of caregivers are hypothesized to be governed
by a common utility function
() k k Z U U = (1)
where Uk denotes their utility in scenario k, which depends
on Zk, the vector of attribute values pertaining to k. Any
alternative, which may affect choice, is included in the vector
of measured attributes z ε Z (McFadden 1983). For instance,
the change in the number of episode-free days from the status
quo constitutes an element of the attribute vector.
Since income Y and out-of-pocket cost pk determine the
number of units xk of the good that can be purchased,
maximum attainable utility not only depends on permit
attributes but income and prices. Thus the indirect utility
function can be written
Vk = V(zk, pk, Y ) = U[Zk
*] (2)
The marginal rate of substitution between two attributes m
and n is given by the ratio of marginal utilities, which
indicates the relative subjective importance of them
(3)
If the variable n in equation (3) is assumed to be price in the
presented context, this can be interpreted as the marginal
WTP for attribute m.
A vector of socioeconomic characteristics h is introduced
into the function to reflect the variability of tastes across
the population to which the model of choice behavior applies
(Ben-Akiva and Lerman 1985)
(4)
It is assumed that the chosen treatment maximizes the
individual’s utility, in keeping with the theory of homus
economicus (McFadden 1983). However, the determinants
of utility are never fully known to the observer, causing
behavior to seemingly have a random component.
Accordingly, the choice probability of alternative k is equal
to the probability that the (indirect) utility of alternative k,
Vk, is greater than or equal to the utility of alternative q,
   q k V V k !   Pr Pr
,   (5)
where Pr(k) is the probability of the caregiver choosing
alternative k. In general, the random utility of an alternative
Table 2 Product attributes and levels retained in the main survey
Attributes Label Levels Value
labels
Episode-free days FREEDAYS Increase from 180 to 200 episode-free days per year 200
Increase from 180 to 220 episode-free days per year 220
Decrease from 180 to 160 episode-free days per year 180
Decrease from 180 to 140 episode-free days per year 140
Exacerbation EXACERBATION Risk of EXACERBATION: 6% of patients develop a mild to severe 6
EXACERBATION
Risk of EXACERBATION: 10% of patients develop a mild to severe 10
EXACERBATION
Risk of EXACERBATION: 16% of patients develop a mild to severe 16
EXACERBATION
Information about INFORMATION INFORMATION available on long-term effects in children between 1
long-term effects by  4 years and 14 years of age
the FDA available
No INFORMATION available on long-term effects in children between 2
4 years and 14 years of age
Out-of-pocket EXPENSES $10 per month 10
EXPENSES $30 per month 30
$50 per month 50
Abbreviations: FDA, Food and Drug Administration.
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can be expressed as a sum of observable (or systematic)
and unobservable components (Louviere et al 2000),
(6)
With this result, equation (5) can now be rewritten as
(7)
Therefore the random element must be dominated by
systematic differences in utility. For further analysis it is
assumed that the error term (εq – εk) is standard normally
distributed. With this assumption, the Probit model can be
applied to estimate Pr(k). Furthermore, assuming the indirect
utility function to be additively separable, the determinants
of V that do not differ between scenarios q and k (in particular
Y and S) drop out of the equation.
Results
Descriptive statistics
In Table 4, descriptive statistics of the caregivers with regard
to the dependent and explanatory variables are reported. Of
all caregivers participating in this study, 19% came from
the Eastern US, 33% from the Midwest, 35% from the South
and 11.9% from the West. Nearly all caregivers who took
part in the survey are female (92.9%), while 7% of caregivers
are fathers or grandparents. The respondents on average have
one child. Forty percent were working full-time and 45%
were homemakers. Most of the study participants reported
not to smoke (71.4%), whereas 16.7% reported to smoke
about one pack of cigarettes per day. The reason for the
high proportion of nonsmokers is to be found in the fact
that the majority of caregivers have also diagnosed asthma
(92.9%) or wheezing conditions (28.6%).
Caregivers were also asked how confident they are in
knowing what they do when thinking about their overall
ability to take care of their family’s general health: eating
right, getting check-ups, taking medicine, and deciding when
to see the doctor. The median for this is 3.5 (standard
deviation of 0.89), with 1 equivalent to “Not at all confident”
and 5 “Extremely confident”. Overall 42.9% of respondents
agreed with the feeling “Very confident” (rating of 3), and
another 26.7% agreed with feeling ”Extremely confident”
(rating of 4). There, 31% felt fairly or somewhat confident,
while 69% felt very or extremely confident. These
descriptive findings suggest that administration of drugs to
the children should be relatively good.
In 18% of cases, physicians never told the caregiver the
diagnosed severity of their child with asthma. Thus, while
21.4% of caregivers rated the severity of their child as very
mild, no physician gave the condition this low rating,
likewise 4.8% of all cases, physicians diagnosed the children
as having severe asthma, compared with 2.4% of caregivers.
Caregivers were also asked to estimate the frequency
with which caregivers (in general) forget to administrate
medication to their child during a week due to several
reasons (job stress, care for other children, etc.). In various
studies, this estimate is as high as 95% (with an average
around 50%) (Peckelman and Sen 1979; Reinhardt 1999).
Respondents estimated that 16.7% of caregivers never forget
during a week. However, when asked about their own
failure, 88.1% say they forget in 19% of all cases.
The characteristics of the children were as follows: the
first born, 33% are male and have a mean age of four years.
Anyway, the second born, 64.3% were male and had a mean
age of 2.8 years (standard deviation 0.96). Notice also that
children with diagnosed asthma have a higher probability
of having allergies in comparison to the average of the same
age (Peckelman and Sen 1979). In this sample, 88% of
children have diagnosed asthma, 26% wheezing conditions,
and 71% have allergies.
Model specification
Since 16 different asthma treatment decisions had to be
evaluated by each respondent, the data are of the panel type.
For this reason, a random effects probit model is used,
assuming responses of a given individual to purchase
questions to be correlated, while answers provided by
different individuals to be uncorrelated.
The first specification test was done on the scaling of
the variables reflecting product attributes. The scaling issue
concerns three product attributes, the episode-free days
(FREEDAYS), the exacerbation probability
(EXACERBATION), and the out-of-pocket expenses
Table 3 Status quo treatment – definition by attribute levels
Attributes Levels
FREEDAYS 180 episode-free days per year
EXACERBATION Risk of EXACERBATION: 10% of
patients develop a mild to severe
EXACERBATION
INFORMATION availability INFORMATION available on long-
term effects in children between 4
years and 14 years of age
Out-of-pocket EXPENSES $20 per month
 k k k k k k W S Y p z W V H H  {    , , ,   
   q q k k W W k H H  !    Pr Pr
  k q k q W W H H   !   Pr
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Table 4 Descriptive statistics of caregivers and their children between 0 and 4 years
Percent Cumulative percent
Gender
  Female 92.9
Age
  <30 years 28.6
  30–39 years 42.8 71.4
  40–49 years 19.1 90.5
  >50 years 9.5 100
Number of children ≤ ≤ ≤ ≤ ≤4 years
  1 child 73.8
  2 children 26.2 100
Rating of healthcare
  Fairly/somewhat confident 31.0
  Very/extremely confident 69.0 100
Number of children with diagnosed asthma and/or wheezing conditions
  1 child 73.8
  2 children 26.2 100
Regions
  East 19.0 19.0
  Midwest 33.3 52.4
  South 35.7 88.1
  West 11.9 100
Relationship to children
  Mother or female guardian 85.7
  Father or male guardian 7.1 92.9
  Grandparent 7.1 100
Level of education
  High school graduate (or lower) 11.9
  Some college 31.0 42.9
  Associate/Bachelor’s degree 40.5 83.3
  Postgraduate school 14.3 97.6*
Current employment situation
  Working full-time 40.5
  Working part-time 11.9 52.4
  Homemaker 45.2 97.6**
Annual household income in 2004
  <US$25 000 4.8
  US$25 000–49 999 45.2 50.0
  US$50 000–74 999 19.0 69.0
  > US$75 000 23.8 92.9***
Nonsmoker 71.4
Severity estimation by caregiver
  Very mild 21.4
  Mild 35.7 57.1
  Moderate 40.5 97.6
  Severe 2.4 100
Severity diagnosis by physician
  Mild 35.7
  Moderate 40.5 76.2
  Severe 4.8 81.0
  Doctor never told me the severity 19.9 100
Compliance estimation for other caregivers
  <20% 54.8
  20%–39% 23.8 78.6
  40%–59% 7.1 85.7
  >60% 14.3 100
Note: *Other education: 2.4%; **Retired: 2.4%; ***Declined to answer: 7.1%.
Continued overTherapeutics and Clinical Risk Management 2007:3(1) 162
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Table 4 Continued
Percent Cumulative percent
Own compliance estimation
  <10% 76.2
  10%–19% 11.9 88.1
  20%–29% 4.8 92.9
  >30% 7.1 100
Children characteristics Percent Cumulative percent
Age
  ≤2 years (child 1) 33.3
  ≤2 years (child 2) 0
Gender
  Female (child 1) 35.7
  Female (child 2) 66.7
Race
  White 88.1
  Black 4.8 92.9
  Other 7.1 100
Number of asthma attacks in the least 4 weeks
  Never 85.7
  A few days 9.5 95.2
  Some/most days 4.8 100
Prevalence of asthma 88.1
Prevalence of wheezing conditions 26.2
Prevalence of allergies 71.4 —
Note: *Other education: 2.4%; **Retired: 2.4%; ***Declined to answer: 7.1%.
(EXPENSES). The discussion will focus on FREEDAYS,
dealing with EXACERBATION and EXPENSES more
concisely. The efficacy in terms of episode-free days was
scaled using two better outcomes than the status quo (180
days) and two worse outcomes: 200 and 220 days for the
better outcomes and 160 and 140 days for the worse one.
However, a linear representation of product attributes would
simplify the calculation of the marginal WTP (MWTP)
values considerably. The evidence suggests that a linear
representation of FREEDAYS is compatible with the data,
as the effect of a reduction in episode-free days from 180 to
160 days cannot be statistically distinguished from the
increase in episode-free days from 180 to 200 days. Also,
episode-free days reductions from 180 to 140 days and the
improvement from 180 to 220 days have the same effect
(close to 22%) according to the data. Therefore, the linear
representation of FREEDAYS may be retained, permitting
the construction of an average value of FREEDAYS and
hence the calculation of MWTP at the sample means.
The same tests for linearity were used for the product
attributes EXACERBATION and EXPENSES. Results
clearly suggest that a linear representation of all parameters
is compatible with the data. A popular alternative is the
quadratic utility function (Gegax and Stanley 1997). The
linearity of the coefficients was analyzed by the Wald test.
In view of the orthogonal design imposed, the utility function
to be tested contained no interaction terms (Johnson et al
1998). Results indicated that the quadratic terms were not
significant at conventional levels, with the one exception
of expenses. However, the estimated coefficient of
(EXPENSES)
2 turned out so small as to make the linear
alternative, evaluated at the mean cost, indistinguishable
from the quadratic. A likelihood ratio test indicated that the
exclusion of all quadratic terms does not entail a significant
loss of explanatory power. Therefore, an indirect utility
function linear in product attributes seems to serve as a
sufficient local approximation to its true counterpart (which
merely needs to be quasiconvex in price).
Up to this point, the specification tests involved only
the product attributes because individual characteristics
should be irrelevant in the choices analyzed if the utility
function is assumed to be additively separable in product
attributes and socioeconomic characteristics. To test this
assumption a model was estimated including interaction
terms between socioeconomic variables and EXPENSES.
From an economic point of view this can be justified since
these interaction terms reflect the marginal utility of money,
which varies with personal characteristics (Vose 2001).
However, all interaction terms lacked statistical significance.
In addition a likelihood ratio test indicated clearly thatTherapeutics and Clinical Risk Management 2007:3(1) 163
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Table 5 Random effects probit estimates for the final model
Variable Coefficient Standard error z P>|z|
FREEDAYS 0.0069* 0.0024 2.85 0.004
EXACERBATION −0.0109 0.0117 −0.93 0.351
INFORMATION −0.3447** 0.1039 −3.32 0.001
EXPENSES −0.0232*** 0.0036 −6.51 0.000
CONSTANT −0.7936 0.4990 −1.59 0.112
Number of observations 756
Chi² (4) 52.48
Prob>chi² 0.0000 Rightly predicted: 0.677
Note:*, **, ***, Coefficient different from zero with an error probability of 5% (1%, 0.1%).
Table 6 Random effects probit estimates for the simulated data (100 Monte-Carlo iterations)
Variable Coefficient Standard error z P>|z|
FREEDAYS 0.0078** 0.0016 4.92 0.000
EXACERBATION −0.0283* 0.0086 −3.28 0.001
INFORMATION −0.5011** 0.0702 −7.14 0.000
EXPENSES −0.0216** 0.0023 −9.53 0.000
CONSTANT −0.5264 0.03134 −1.68 0.093
Number of observations 1600
Chi² (4) 142.48
Prob>chi² 0.0000 Rightly predicted: 0.689
Note: *, **, Coefficient different from zero with an error probability of 5% (1%, 0.1%).
including interaction terms does not improve goodness of
fit of the model. This finding is in agreement with the
assumption of a utility function which is additively
separable.
The estimates of the final random effect probit model
(which contains only the four product attributes in linear
form, including EXPENSES) are presented in Table 5 for
the original data. All product attributes are highly significant
except for EXACERBATION and the constant. This is of
particular interest since the attribute EXACERBATION was
one of the four most important attributes in the pretest
interviews. One possible reason why this attribute is
nonsignificant is the low number of respondents. Due to
budget restrictions, only 42 respondents could be included
in the survey. However, to improve the validity and
significance of the study, the data have also been simulated
by 100 Monte-Carlo iterations. For this the binomial
distribution was assumed for the simulation of the outcome
“Scenario”. For the caregiver’s socioeconomic
characteristics, a beta-pert distribution was assumed to stay
within the calculated ranges of the parameters given by the
study participants (Zweifel et al 2004). It turned out that
also the attribute EXACERBATION is highly significant
when using 100 iterations (see Table 6), which was used as
having 100 respondents.
Willingness-to-pay
The calculation of MWTP for an improvement or reduction
of episode-free days is based on equation (3). Since the
indirect utility function is linear in its arguments, the
marginal rate of substitution between the change in episode-
free days and the out-of-pocket expenses for a treatment of
caregiver’s child amounts to a division of the regression
coefficient pertaining to FREEDAYS by the coefficient
pertaining to EXPENSES.
MWTP per month for 20 additional episode-free days
due to a new treatment turns out to be US$6.00 (=−0.0069/
−0.0231). A standard prediction in the theory of health
economics is that individuals with a higher risk aversion
should have a higher MWTP for a better outcome such as
an improvement of episode-free days (Janse et al 2004).
However as previously explained, risk aversion is one of
the personal characteristics that should not influence the
decision.
An interesting question from the (industry) policy point
of view for possible new products is the amount of WTP
for the product as a whole. Assuming that the final model is
correctly specified, the (negative) constant may be
interpreted as indicating that caregivers feel confident with
the asthma treatment options already on the market and
having hence not a positive assessment of a new treatment.Therapeutics and Clinical Risk Management 2007:3(1) 164
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From this benchmark, one may integrate the MWTP over
the four attributes distinguished to obtain WTP for the
product as a whole. As shown in Table 7, a treatment having
average features with regard to each of the three attributes
distinguished evokes a small but positive WTP (US$1.65).
The attributes for this average product is defined as having
no improvement in episode-free days, a probability of 6%
to develop an exacerbation and information available by
the FDA. The maximum WTP (US$13.54) for a new asthma
treatment could be achieved with a maximum of
improvement in episode-free days (220 days per year), 6%
probability of exacerbation and information available by
the FDA.
Out of the 16 variants described, one fourth of the
treatment options have a positive average WTP. The negative
WTP observed raises the issue of future product
development and provision of information to potential users.
As can be gleaned from Table 7, one increment on the scale
of FREEDAYS (4 levels) is worth US$0.30 (=0.0069/
0.0232). This means that a status quo of 180 episode-free
days (Pauwels et al 1997) lead to WTP of US$53.53 with
everything else held constant. In the case of
EXACERBATION, this figure amounts to a negative
amount of US$0.47 per percentage point of exacerbation
probability. The available information from the FDA shows
a worth of US$14.86. Therefore, assuming equal
productivity of research and development efforts, these
efforts should be directed at improved efficacy (episode-
free days). Also, information about improvements and safety
may prove of particular importance for encouraging the
purchase and use of (new) asthma treatments for children.
Discussion and conclusion
To the best of our knowledge this study is the first one to
analyze the impact of various treatment attributes on the
WTP of caregivers for their preschool children. The sample
size is relatively small due to budget restrictions. However,
the results should be important in the rating of WTP and
utility estimations in preschool children in chronic diseases
such as asthma. Due to the fact that individuals have
difficulties when dealing with probabilities (Tversky and
Kahneman 1974), the measurement of the MWTP for an
improvement in episode-free days (using probability) may
lead to particular challenges. First, the individuals concerned
probably are not only interested in the aspect of the change
in efficacy (assumed to be episode-free days), but may
consider other aspects of asthma treatment, such as the
possibility to develop an asthmatic exacerbation or available
information by the FDA (information on long-term effects
in children between 4 and 14 years of age) as well as
expenses. Secondly, the population of interest is of low age
(between 0 and 4 years), which leads to the fact that these
could not be included in the study due to natural limitations.
Hence the caregivers of the target population were included
in the survey as an approximation. This assumption could
be verified due to the fact that the caregivers must decide
which treatment (if any) should be offered to their child
and to which price. Additionally it can be assumed that
caregivers also want to maximize the utility (and quality of
life) of their child.
Discrete-choice experiments required respondents to
only indicate whether they prefer one scenario over another.
Moreover, it was possible to use the status quo as the
reference scenario. Based on random utility theory, a binary
purchase decision equation was specified and estimated
using probit. Several tests were performed with regards to
the scaling of the attribute variables, the linearity of the
utility function used, and the derivation of a final model.
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Appendix
Appendix 1 An example of a card presented to respondents
is shown in Table A1.
Appendix A1 Example of a card presented to respondents
AGENT A AGENT B
Episode free days 180 episode-free 220 episode-free days
days per year  per year
Exacerbation Risk of exacerbation: Risk of exacerbation:
10% of patients 16% of patients
develop a mild to develop a mild to
severe exacerbation severe exacerbation
Information Information available Information available
availability on long-term effects on long-term effects in
in children between children between
4 years and 14 years 4 years and 14 years
of age  of age
Out-of-pocket $20 $50
expenses
OO